Image via Globe & Mail Business
CGI: Leadership Change
Tim Hurlebaus appointed as President and Chief Executive Officer
Source: Globe & Mail Business
The leadership read
Leadership transitions often precede broader sales bench-strengthening over the next two quarters.
Market context: Against a Talent Market Index of 98.6 (Neutral) (down 1.4 month-on-month), EMEA is at steady (-1.1pts) on signal share.
CGI: 2 signals in the last 90 days — above the Sales median of 1 across 25 tracked companies; 0.1% of MitchelLake's Americas signal flow; 2 tracked across 35 days.
MitchelLake in this thematic
From the MitchelLake archive
Also at CGI →
More signals across Sales
Leadership Change · EMEA
Okta →Eric Kelleher, President and COO of Okta, is driving major organizational transformation around AI integration. He's implementing new work design frameworks that treat AI agents as colleagues alongside human workers, requiring managers to budget for 'digital labor' alongside headcount.
Leadership Change · EMEA
Trustpilot →Trustpilot appointed John-Paul Savant as non-executive director, former CEO of Auction Technology Group with 20 years digital marketplace experience
Partnership · EMEA
NICE Actimize →NICE Actimize won a major mandate with DNB Bank ASA (Norway's largest financial services group) to deploy X-Sight Enterprise platform for fraud and financial crime detection. Infosys selected as systems integration partner for end-to-end modernization.
Partnership · EMEA
Napier AI →Napier AI partnered with Concentrix to expand its Continuum compliance platform into ANZ markets, leveraging Concentrix's scale and transformation expertise to serve financial services organizations.
Capital Raising · EMEA
Liftoff Mobile →Liftoff Mobile completed IPO on Nasdaq, raising $437 million. CEO Jeremy Bondy led the company public after market stabilization, achieving tenth consecutive quarter of growth. Backed by Blackstone private equity.
Product Launch · EMEA
Novo Nordisk →Novo Nordisk's investigational zenagamtide (once-weekly GLP-1 receptor agonist) demonstrated significant A1C reductions and up to 14.6% weight loss in Phase 2 study of adults with type 2 diabetes, presented at ADA 2026
Intelligence powered by Autonodal ↗